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Abstract
We recently reported the medicinal chemistry re-optimization of a series of compounds
derived from the human tyrosine kinase inhibitor, lapatinib, for activity against Plasmodium
falciparum. From this same library of compounds, we now report potent compounds against
Trypanosoma brucei brucei (which causes human African trypanosomiasis), T. cruzi (the
pathogen that causes Chagas disease), and Leishmania spp. (which cause leishmaniasis).
In addition, sub-micromolar compounds were identified that inhibit proliferation of the para-
sites that cause African animal trypanosomiasis, T. congolense and T. vivax. We have
found that this set of compounds display acceptable physicochemical properties and repre-
sent progress towards identification of lead compounds to combat several neglected tropical
diseases.
Author summary
As part of our efforts to identify compounds that are active against the parasite that causes
malaria (P. falciparum), we employed a “parasite hopping” approach in our drug discov-
ery efforts. This involved screening a library of demonstrated antiparasitic agents against
other parasites responsible for a host of neglected tropical diseases (NTDs) including Cha-
gas disease (T. cruzi), human African trypanosomiasis (T. brucei) and cutaneous leish-
maniasis (L. major). The compounds we identified generally show improved selectivity
for the parasite of interest over the mammalian cell lines tested and, from this work, we
have made progress towards the identification of lead compounds against multiple NTDs.
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Introduction
Neglected tropical diseases (NTDs) are a collection of 20 communicable diseases [1]. Though
mostly treatable and/or preventable, NTDs remain a leading cause of morbidity and mortality
affecting over 1 billion people worldwide. Many of the current treatments have significant side
effects, poor efficacy and there are increasing reports of resistance in the literature [2, 3]
highlighting the need for novel chemotherapeutics. Collectively, 17 of these NTDs account for
26 million disability-adjusted life years (DALY) [4], which is a sum of years of life lost due to
premature mortality and those lost due to ill health or disability. In addition, livestock are also
susceptible to various parasitic infections, and can lead to the development of diseases such as
African animal trypanosomiasis (AAT), which has devastating economic effects on communi-
ties. AAT is caused by infection with T. congolense or T. vivax [5], and of the three main che-
motherapeutics currently listed for treatment, diminazene aceturate and isometamidium
chloride are the most widely used [6], though reports of resistance are increasing to both of
these [7–8].
As part of our efforts to identify new drugs for human African trypanosomiasis (HAT), we
undertook a target class repurposing project [9], wherein we screened known human tyrosine
kinase inhibitors against a number of pathogenic protozoan parasites (Fig 1). Historically, we
have cross-screened our compounds against P. falciparum, T.b. brucei, T. cruzi, and L. major
to fully leverage chemical space covered by our optimization campaign [10]. This cross-screen-
ing led to the identification of 1 [10] as a potent inhibitor of proliferation of P. falciparum, T.b.
brucei and T. cruzi. Herein, we report the results of a screening campaign using a set of previ-
ously reported, structurally related compounds previously optimized for their activity against
Fig 1. Project progression has led to the identification of potent inhibitors of P. falciparum, T.b. brucei, T. cruzi, and L. major through variations of the head
region (shown in blue) and the linker/tail region (shown in red) from lapatinib [12] to compounds typified by 1. Desired ranges for physicochemical properties:
cLogP:�3, lipophilic ligand efficiency (LLE = pEC50—cLogP):�4 [13], aqueous solubility:> 10 μM.
https://doi.org/10.1371/journal.pntd.0006834.g001
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P. falciparum [11]. We screened these compounds for activity against T.b. brucei, T. cruzi and
L. major and we also report activity data for a subset of these compounds against T. congolense
and T. vivax. The previously reported P. falciparum data for these compounds, along with
additional screening data that is not discussed directly in this study, is provided in the Supple-
mentary Information, S1 Table.
Established target product profiles for Chagas disease, leishmaniasis and HAT, were used to
define hit and lead candidate criteria (summarized in the Supplementary Information, S2
Table) [14–15]. We note that, according to a committee coordinated by the Global Health
Innovative Technology Fund (GHIT), a hit compound for Chagas disease or leishmaniasis
should have an EC50 < 10 μM [15].
Results and discussion
Trypanosoma cruzi
When tested against intracellular T. cruzi parasites, several compounds displayed low micro-
molar inhibition of T. cruzi, and these included truncated head groups 3-chloro-4-methoxy-
phenyl (6, EC50: 3.8 μM) and para-methoxyphenyl (9, EC50: 1.9 μM), as well as the para-
trifluoromethoxyphenyl (10, EC50: 1.4 μM) analog (Fig 2). Removal of the phenylsulfonamide
and replacement with the para-substituted pyrimidine (14, EC50: 0.090 μM) (Fig 3) led to the
most potent compound against T. cruzi identified in this series and afforded a significant
boost in selectivity index (SI) versus 3T3 cells (SI: 170). Other submicromolar compounds
were identified, such as the pyrazole analog (16, EC50: 0.92 μM) and the t-butyl carbamate (21,
EC50: 0.60 μM), though selectivity versus 3T3 cells was an issue for 16 in particular (SI: 2.5).
An additional compound, 23 (EC50: 0.62 μM) (Fig 4), had an improved lipophilic ligand effi-
ciency [13] (LLE; 1.8 compared to -0.29 for 1, see Supplementary Information, S3 Table for a
complete list of values) and maintained potent inhibition of T. cruzi, though the aqueous solu-
bility was poor (<1 μM, see Supplementary Information, S4 Table for complete list of
ADME values) and the human liver microsome intrinsic clearance (HLM Clint: 170 μL/min/
mg), and rat hepatocyte intrinsic clearance (RH Clint: 45 μL/min/106 cells) were both high.
Importantly, host cell toxicity (3T3 cells) was generally low for the series, and the selectivity
index (SI) was above the targeted 10×EC50 threshold. The general SAR trends observed for this
series against T. cruzi are summarized in Fig 5.
Leishmania major
Some of the SAR trends observed with T. cruzi were mirrored in L. major. Truncation of the
head group to the 3-chloro-4-methoxyphenyl (6, EC50: 1.4 μM), 3-chlorophenyl (7, EC50:
3.4 μM), para-methoxyphenyl (9, EC50: 4.4 μM), and the para-trifluoromethoxyphenyl (10,
EC50: 0.78 μM) all led to potent analogs (Fig 2). In addition, several pyridyl (5, and 11), and
pyrimidine (2) derivatives exhibited potent inhibition (EC50 values ranging from 2.1–3.9 μM).
The meta- substituted sulfonamide analog (13) was the most potent compound identified
(EC50: 0.20 μM) and suggested that the change in vector may be favorable (Fig 3). This idea
was supported by the thiadiazole analog 15 (EC50: 0.96 μM) which possesses a more acute vec-
tor than 13 yet maintains potency. In addition, compound activity remained upon removal of
the tail group (red in Fig 1) and replacement with the t-butyl carbamate (21, EC50: 1.1 μM) or
pyrazole (16, EC50: 0.83 μM). Finally, removal of the sulfonamide and replacement with the
pyrimidine (14; EC50: 1.5 μM), as well as incorporation of an -NH linker (17–20), led to several
compounds with low-micromolar inhibition (EC50 values ranging from 0.87–2.5 μM) of L.
major. Importantly, host cell toxicity (HepG2) was found to be low for these analogs and the SI
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was greater than the 10×EC50 threshold that was targeted. The general SAR trends around this
series for activity against L. major are summarized in Fig 6.
Trypanosoma brucei brucei
With a reduction of the lipophilicity of the head group several sub-micromolar inhibitors of T.
b. brucei, including para substituted pyridines (5, 11 and 12; EC50 values ranging from 0.27–
0.70 μM), pyrazines (3 and 4; EC50: 0.62 and 0.91 μM respectively) and several substituted ani-
lines (6, 8 and 10; EC50 values ranging from 0.22–0.65 μM) were identified (Fig 2). Replace-
ment of the phenylsulfonamide with the pyrimidine (14; EC50: 0.0060 μM) (Fig 3) led to a
10-fold improvement in potency over 1 (EC50: 0.079 μM). Additionally, incorporation of an
-NH linker led to compounds with an improvement in potency (17–20; EC50 values ranging
Fig 2. Biological activity of key compounds with varying head groups (denoted by R1) against L. major
amastigote, T.b. brucei, T. cruzi cultures and HepG2 human cells. Data for the full screening set is summarized in
the supplementary information. nd = not determined aAll r2 values are>0.9 unless noted otherwise bAll SEM values
within 25% except for 1 where EC50 T. cruzi 0.73 (SEM: 0.2; 27%) cTested concentration ranges were determined based
on compound solubility dSelectivity index (SI) calculated relative to HepG2 cells. eSelectivity index (SI) calculated
relative to 3T3 cells.
https://doi.org/10.1371/journal.pntd.0006834.g002
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from 0.098–0.16 μM). A combination of the pyrazine head group with the pyrimidine tail (22;
EC50: 0.43 μM) (Fig 4) produced a sub-micromolar inhibitor of T.b. brucei proliferation. This
compound had a significantly improved LLE above the desired range (4.3), and improved
aqueous solubility (44 μM), though HLM (Clint: 180 μL/min/mg) and RH clearance (Clint:
130 μL/min/106 cells) are still of concern and require further optimization. The general SAR
trends around this series for activity against T.b. brucei are summarized in Fig 7.
Given the activity observed against T.b. brucei, a selection of compounds that demonstrated
sub-micromolar inhibition of T.b. brucei were further profiled against T. congolense and T.
vivax, which are the main causative agents for African animal trypanosomiasis (AAT)
(Table 1), to determine how well the activity translated to these closely related kinetoplastids
Fig 3. Biological activity of key compounds with varying tail groups (denoted by R2) against L. major amastigote,
T.b. brucei, T. cruzi cultures and HepG2 human cells. Data for the full screening set is summarized in the
supplementary information. nd = not determined aAll r2 values are>0.9 unless noted otherwise bAll SEM values
within 25% except for 1 where EC50 T. cruzi 0.73 (SEM: 0.2; 27%) cTested concentration ranges were determined based
on compound solubility dSelectivity index (SI) calculated relative to HepG2 cells. eSelectivity index (SI) calculated
relative to 3T3 cells.
https://doi.org/10.1371/journal.pntd.0006834.g003
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[5]. All of the analogs screened were observed to be sub-micromolar against both T. congolense
and T. vivax. Compounds 22 and 23 were observed to be more potent than diminazene for T.
congolense (EC50: 0.050 μM), and T. vivax (EC50: 0.040 μM), respectively. None of the com-
pounds tested were more potent than isometamidium against either species.
We selected the most promising T. brucei inhibitor (14) for pharmacokinetic (PK) analysis
on the basis of its high potency (EC50: 0.0060 μM). PK parameters were measured for both
brain and plasma following a single intraperitoneal (i.p.) dose of 10 mg/kg (see Supplemen-
tary information, S5 and S6 Tables). To achieve efficacy in the in vivo acute HAT model, we
were aiming to exceed 10×EC50 for 6–8 h, though at this dose we were only able to exceed
these levels for 4 h in plasma (see Supplementary information, S1 Fig). Further, 14 had an
Fig 4. Biological activity of key compounds that combine head (R1) and tail (R2) groups against L. major amastigote, T.b. brucei,
T. cruzi cultures and HepG2 human cells. Data for the full screening set is summarized in the supplementary information.
nd = not determined aAll r2 values are>0.9 unless noted otherwise bAll SEM values within 25% except for 1 where EC50 T. cruzi 0.73
(SEM: 0.2; 27%) cTested concentration ranges were determined based on compound solubility dSelectivity index (SI) calculated
relative to HepG2 cells. eSelectivity index (SI) calculated relative to 3T3 cells.
https://doi.org/10.1371/journal.pntd.0006834.g004
Fig 5. SAR summary around this series for potent anti-T. cruzi activity.
https://doi.org/10.1371/journal.pntd.0006834.g005
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excellent brain to plasma exposure ratio of 7.4, which was encouraging given CNS exposure is
required to treat stage 2 HAT infections, when parasites have crossed the blood-brain barrier
[16].
Given that the PK results of 14 indicated a higher dose would be required to achieve
10×EC50, we administered a single i.p. dose of 25 mg/kg in a murine model of acute HAT.
Control mice received an i.p. dose of drug vehicle (dimethylsulfoxide, 3.4 mL/kg). There was
no evidence of toxicity and a 10-fold reduction in parasitemia was observed in 75% of mice
dosed with 14 while one had no detectable parasitemia (see Supplementary information, S2
Fig).
Given the improvements in the overall ADME profile of 22, coupled with its sub-micromo-
lar inhibition of T.b. brucei we sought to progress it into an efficacy study. Mice were adminis-
tered orally (p.o.) once daily 60 mg/kg for the first three days post-infection. Observing no
signs of toxicity, the dose was increased to 70 mg/kg for the remaining three days of treatment.
Control mice received a p.o. dose of drug vehicle (10% NMP and 90% PEG, 10 mL/kg). By day
5, there was no statistically significant difference between the control group and the group
treated with 22 (Fig 8).
In summary, by screening a series of anti-P. falciparum proliferation inhibitors against
kinetoplastids, we have identified several potent compounds against T. cruzi, L. major, and T.
Fig 6. Series SAR summary for anti-L. major activity.
https://doi.org/10.1371/journal.pntd.0006834.g006
Fig 7. SAR summary around this series for potent anti T.b. brucei activity.
https://doi.org/10.1371/journal.pntd.0006834.g007
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b. brucei. When taken in its entirety, this set of compounds generally shows low host cell toxic-
ity and the analogs had good to excellent selectivity for the parasite of interest. Of note was the
identification of 22 which exhibited potent inhibition of T.b. brucei, and an improved ADME
profile but, when it was progressed into an in vivo model of acute HAT infection, failed to
affect parasitemia. We are working to ascertain the reasons for the lack of translation from in
vitro to in vivo and we continue to pursue further optimization of this series as anti-trypanoso-
mal and anti-leishmanial lead compounds, the results of which will be reported in due course.
Materials and methods
Trypanosoma brucei
The assay was performed following a previously reported procedure [17]. Briefly, in a 96-well
plate, compounds were added in triplicates at 50 μM and in serial dilutions 1:2 in HMI-9
Table 1. Biological activity against T. congolense and T. vivax.
ID T. b. brucei EC50 (μM) T. congolense EC50 (μM) T. vivax EC50 (μM)
1 0.080 0.14 0.040
6 0.22 0.86 0.16
14 0.0060 0.16 0.20
15 0.14 0.39 0.21
16 0.11 0.47 0.15
21 0.15 0.83 0.29
22 0.43 0.050 0.72
23 0.91 0.14 0.040
Diminazene 0.0090 0.13 0.10
Isometamidium nt 0.0060 0.00012
nt = not tested
https://doi.org/10.1371/journal.pntd.0006834.t001
Fig 8. Parasitemia levels of T. b. brucei infected mice treated with 60 mg/kg 22 for the first three days post-infection before the dose was increased to 70
mg/kg for the remainder of the study, compared with the control group (10% NMP and 90% PEG only). Compound 22 and vehicle were administered
once p.o. on Day 1 post-infection. Parasitemia in the blood collected from the tail vein was determined on Days 2–6 post-infection. UND: Undetectable
parasitemia (<2×104 cells/mL), the black horizontal line in each group indicates the median parasitemia level. The different shapes are representative of each
mouse in the group. NS: Not significant. The error bar indicates the standard error of the mean (SEM). The significance of the difference in the mean
parasitemia of treated and untreated groups was analyzed by Student’s T-test.
https://doi.org/10.1371/journal.pntd.0006834.g008
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medium. To each well, 100 μL of 2.5×103 T. b. brucei (strain 427, received as a gift from Dr. C.
C. Wang at UCSF) in HMI-9 medium was were added and incubated at 37˚C, 5% CO2 for 48
h. Following incubation, 20 μL of PrestoBlue were added to each well and incubated for addi-
tional 4 h. Fluorescence was read at 530 nm excitation and 590 nm emission. Suramin at
100 μM was used as positive control and reference for calculation of IC50.
Ethics statement
This study was carried out in strict accordance with the USA Public Health Service Policy on
Humane Care and Use of Laboratory Animals and Association for Assessment and Accredita-
tion of Laboratory Animal Care accreditation guidelines. All mice were maintained in the Uni-
versity of Georgia Animal Facility under pathogen-free conditions. The protocol (AUP #
A2013 06-011-A10) was approved by the University of Georgia Institutional Animal Care and
Use Committee.
Mouse infection with T. b. brucei
Bloodstream form (BSF) T. brucei brucei CA427 parasites were maintained at densities below
1×106 cells/mL in HMI-9 media supplemented with 10% fetal bovine serum (Atlanta Biologi-
cals), 10% SERUM PLUS (Sigma), and 1% Antibiotic-Antimycotic Solution (Corning cellgro)
at 37˚C, 5% CO2 [18]. Parasites were centrifuged at 5000 xg for 3 min at room temperature
and resuspended in cold 1xPBS containing 1% glucose to yield a solution of 2.5×106 cells/mL.
Correct cell density following resuspension was confirmed using a Z2 Coulter Counter (Beck-
man). Parasite viability was observed by motility with a Neubauer Bright-line hemocytometer.
Cells were kept on ice until infection.
Compound 14 –on day 0, female Swiss-Webster mice (8–10 weeks old, 20–25 g, n = 4 per
group) (Harlan) were infected i.p. with 2.5×105 trypanosomes by injecting 100 μL of resuspen-
sion using 26G needles. Day 1 to 3 post-infection, mice received a single i.p. dose of either
drug vehicle (dimethylsulfoxide, 3.4 mL/kg) (Fisher Scientific) or drug (14, 25 mg/kg). Parasi-
temia was determined on days 2 and 3 post-infection by collecting 3 μL of blood from the tail
vein.
Compound 22 –on day 0, female Swiss-Webster mice (8–10 weeks old, 20–25 g, n = 4 per
group) were infected i.p. with 1×105 trypanosomes by injecting 100 μL of resuspension using
26G needles. Day 1 to 3 post-infection, mice received a single p.o. dose of either drug vehicle
(10% NMP and 90% PEG, 10 mL/kg) (Fisher Scientific) or drug (22, 60 mg/kg). From days 4
to 6, the dose was increased to 70 mg/kg for the mice in the treatment group. Parasitemia was
determined on days 3 to 6 post-infection by collecting 3 μL of blood from the tail vein.
Blood samples were mixed with 21 μL of RBC Lysis Solution (Qiagen) and incubated at
room temperature for 15–45 min prior to observing for parasites by hemocytometer. Humane
euthanasia by CO2 overdose followed by incision to form a bilateral pneumothorax was con-
ducted on mice at study termination. All animal experimental protocols were approved and
performed in accordance with the guidelines of the Institutional Animal Care and Use Com-
mittee (IACUC) at the University of Georgia.
Trypanosoma cruzi
In a 96-well plate, 5×104 3T3 cells in DMEM without phenol red supplemented with 2% FBS
were added to each well. Cells were incubated for 2 h to allow for attachment. Compounds were
added in triplicates at 50 μM and in serial dilutions 1:2. To each well, 5×104 T. cruzi trypomasti-
gotes (Tulahuen strain expressing β-galactosidase) were added and incubated at 37˚C, 5% CO2
for 96 h. Following incubation, 50 μL of 500 μM chlorophenol Red-β-D-galactopyranoside
Anilinoquinoline based inhibitors of trypanosomatid proliferation
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(CPRG) in phosphate-buffered saline with 0.5% NP40 was added to each well and incubated at
37˚C, 5% CO2 for 4 h. Absorbance was read at 590–595 nm. Amphotericin B at 4 μM was used
as positive control and reference for calculation of EC50.
Trypanosoma congolense
In vitro drug sensitivity assay for T. congolense (72 h): Compounds were tested in vitro for effi-
cacy against the IL3000 T. congolense (drug sensitive) strain which was originally derived from
the Trans Mara I strain, isolated from a bovine in 1966 in Kenya [19]. In brief, test compounds
were prepared as 10 mg/mL DMSO stocks for each assay run, data points were averaged and
EC50 values were determined using Softmax Pro 5.2 (Molecular Devices, Inc.). Compounds
were assayed in at least three separate, independent experiments and an 11-point dilution
curve was used to determine the EC50 values. Bloodstream form trypanosomes were supported
in HMI-9 medium containing 20% bovine serum and were incubated with test compounds for
69 h at 34˚C in a humidified atmosphere containing 5% CO2. Thereafter, 10 μL of Resazurin
dye (12.5 mg in 100 mL of phosphate-buffered saline, Sigma-Aldrich, Buchs, Switzerland) was
added for an additional 3 h. Plates were read using a fluorescence plate reader (Spectramax,
Gemini XS, Bucher Biotec, Basel, Switzerland) using an excitation wavelength of 536 nm and
an emission wavelength of 588 nm.
Trypanosoma vivax
Ex vivo drug sensitivity assay for T. vivax (48 h): Compounds were tested ex vivo against the
STIB 719 / ILRAD 560 T. vivax (drug sensitive) strain which originated from the Y486 strain,
isolated from a naturally infected bovine in 1976 in Zaria, Nigeria [19]. Compounds were
assayed in at least three separate, independent experiments and an 11-point dilution curve was
used to determine the EC50 values. Bloodstream form trypanosomes were harvested from a
highly parasitaemic mouse (via cardiac puncture) and were incubated with test compounds
for 45 h at 37˚C in a humidified atmosphere containing 5% CO2, supported in HMI-9 medium
containing 20% bovine serum. Thereafter, Resazurin dye was added to monitor trypanosome
viability as described in the preceding section.
Leishmania major
Amastigote assays were performed using pLEXSY-hyg2-luciferase L. major transfected pro-
mastigotes and the murine RAW 264.7 macrophage cell line (ATCC TIB-71, Manassas, VA).
Briefly, luciferase-expressing promastigotes of each Leishmania species were generated by add-
ing a luciferase encoding region to the pLEXSY-hyg2 vector (Jena Biosciences, Germany) as
described [20]. One μg of the linearized pLEXSY-hyg2-luciferase vector were electroporated
(480 V, 13 O, and 500 μF) into 4×107 Leishmania promastigotes. Selection for stable promasti-
gote transfectants was carried out using hygromycin B (100 μg/mL). RAW 264.7 macrophages
were maintained in growth medium (Dulbecco’s Modified Eagle’s Medium supplemented
with heat-inactivated 10% FBS (Life Technologies)). Cells were harvested and resuspended in
growth medium at 2.0×105 cells/mL, and 1×104 cells/well were dispensed (final volume 50 μL)
in each well of a 384 well tissue-culture treated white plate using a EVO Freedom liquid han-
dling system (Tecan, Durham, NC). Plates were incubated at 37˚C in 5% CO2 for 24 h after
which the culture medium was removed from each well using the EVO Freedom liquid han-
dler. Metacyclic phase pLEXSY-hyg2-luciferase-Leishmania promastigotes (MOI = 1:10 L.
major) were added to each assay plate well and allowed to infect the RAW 264.7 macrophages.
After an overnight incubation, the growth medium was aspirated and each well was washed
three times with 40 μL of fresh growth medium to remove non-internalized promastigotes.
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After the third wash, 69.2 μL of growth medium was added to each well. Compound dilutions
(final concentration ranges 0.5–10,000 ng/mL) were generated and dispensed using the liquid
handling system. Compound treated plates were incubated at 37˚C in 5% CO2 for 96 h. After
incubation, 7.5 μL of a luciferin solution (Caliper Life Science, Waltham, MA) diluted to
150 μg/mL was added to each well, and the plates were incubated for 30 min at 37˚C in the
dark. Data were captured using an Infinite M200 plate reader (Tecan). EC50s were generated
for each concentration response test using GraphPad Prism software 6.0.
Drug toxicity to 3T3 cells
In a 96-well plate, 5×104 NIH/3T3 (ATCC CRL-1658) cells (purchased from ATCC) in
DMEM without phenol red supplemented with 2% FBS were added to each well. Cells were
incubated for 2 h to allow for attachment. Compounds were added in triplicates at 200 μM and
in serial dilutions 1:2 and incubated at 37˚C, 5% CO2 for 96 h. Ionomycin at 100 μM was used
as positive control and reference for calculation of EC50. Following incubation, 10 μL of Ala-
mar Blue (ThermoFisher) were added to each well and cells incubated at 37˚C, 5% CO2 for 4
h. Absorbance was read at 590–595 nm.
Drug toxicity to HepG2 cells [21]
HepG2 cells were cultured in complete Minimal Essential Medium prepared by supplementing
MEM with 0.19% sodium bicarbonate, 10% heat inactivated FBS, 2 mM L-glutamine, 0.1 mM
MEM non-essential amino, 0.009 mg/mL insulin, 1.76 mg/mL bovine serum albumin, 20
units/mL penicillin–streptomycin, and 0.05 mg/mL gentamycin. HepG2 cells cultured in com-
plete MEM were first washed with 1× Hank’s Balanced Salt Solution (Invitrogen #14175095),
trypsinized using a 0.25% trypsin/EDTA solution, assessed for viability using trypan blue, and
resuspended at 250,000 cells/mL. Using a Tecan EVO Freedom robot, 38.3 μL of cell suspen-
sion were added to each well of clear, cell culture-treated 384-well microtiter plates for a final
concentration of 9570 liver cells per well, and plated cells were incubated overnight in 5% CO2
at 37˚C. Drug plates were prepared with the Tecan EVO Freedom using sterile 96 well plates
containing twelve duplicate 1.6-fold serial dilutions of each test compound suspended in
DMSO. 4.25 μL of diluted test compound was then added to the 38.3 μL of media in each well
providing a 10%-fold final dilution of compound. Compounds were tested from a range of 57
ng/mL to 10,000 ng/mL for all assays. Mefloquine was used as a plate control for all assays with
a concentration ranging from 113 ng/mL to 20,000 ng/mL. After a 48 h incubation period,
8 μL of a 1.5 mg/mL solution of MTT diluted in complete MEM media was added to each well.
All plates were subsequently incubated in the dark for 1 h at room temperature. After incuba-
tion, the media and drugs in each well was removed by shaking the plate over sink, and the
plates were left to dry in a fume hood for 15 mins. Next, 30 μL of isopropanol acidified by addi-
tion of HCl at a final concentration of 0.36% was added to dissolve the formazan dye crystals
created by reduction of MTT. Plates are put on a 3-D rotator for 15–30 mins. Absorbance was
determined in all wells using a Tecan iControl 1.6 Infinite plate reader. The 50% toxic concen-
trations (TC50) were then generated for each toxicity dose response test using GraphPad Prism
(GraphPad Software Inc., San Diego, CA) using the nonlinear regression (sigmoidal dose-
response/variable slope) equation.
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